1,988,780 Shares in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Acquired by Dauntless Investment Group LLC

Key Points

• Dauntless Investment Group LLC invested approximately $2.53 million in OKYO Pharma Limited, acquiring nearly 2 million shares, making it the firm's second largest holding at 3.0% of its portfolio.
• OKYO Pharma's current stock price is $2.73, with a 12-month trading range between $0.81 and $3.11 as analysts maintain a "buy" rating with a target price of $7.00.
• The company is focused on developing therapeutics for inflammatory eye diseases, with its lead candidate, OK-101, currently in Phase II clinical trials for treating dry eye disease.

Dauntless Investment Group LLC purchased a new stake in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,988,780 shares of the company's stock, valued at approximately $2,526,000. OKYO Pharma accounts for 3.0% of Dauntless Investment Group LLC's investment portfolio, making the stock its 2nd biggest holding. Dauntless Investment Group LLC owned about 5.88% of OKYO Pharma as of its most recent filing with the Securities & Exchange Commission.

Separately, FNY Investment Advisers LLC bought a new position in shares of OKYO Pharma in the first quarter valued at approximately $25,000. Institutional investors own 2.97% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of OKYO Pharma in a report on Monday, May 5th.

OKYO Pharma Trading Up 14.4%

Shares of OKYO Pharma stock traded up $0.39 on Friday, hitting $3.09. The company had a trading volume of 684,755 shares, compared to its average volume of 171,796. The business has a 50-day simple moving average of $2.45 and a 200-day simple moving average of $1.67. OKYO Pharma Limited Sponsored ADR has a 52 week low of $0.81 and a 52 week high of $3.11.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.